Company Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.

Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.

The company is based in London, the United Kingdom.

Akari Therapeutics, Plc

Country	United Kingdom
Industry	Biotechnology
Sector	Healthcare
Employees	9
CEO	Ms. Rachelle Suzanne Jacques

Contact Details

Address: 22 Boston Wharf Road, Fl 7 Boston, Massachusetts 02210 United States
Phone	(646) 350-0702
Website	akaritx.com

Stock Details

Ticker Symbol	AKTX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001541157
CUSIP Number	00972G108
ISIN Number	US00972G2075
Employer ID	98-1034922
SIC Code	2834

Key Executives

Name	Position
Rachelle Suzanne Jacques	President, Chief Executive Officer and Director
Wendy F. DiCicco CPA	Interim Chief Financial Officer
Melissa Bradford-Klug	Chief Operating Officer
Dr. Miles Nunn	Chief Scientific Officer
Dr. John F. Neylan III, M.D.	Executive Vice President and Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Apr 11, 2024	8-K	Current Report
Apr 1, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 11, 2024	425	Filing
Mar 11, 2024	8-K	Current Report
Mar 5, 2024	425	Filing
Mar 5, 2024	8-K	Current Report
Jan 9, 2024	D	Notice of Exempt Offering of Securities
Jan 4, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership
Jan 2, 2024	8-K	Current Report

View All SEC Filings